Fredrick M Wigley

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Clinical practice. Raynaud's Phenomenon
    Fredrick M Wigley
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    N Engl J Med 347:1001-8. 2002
  2. ncbi request reprint "Still" ill?
    Peter K Wung
    Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Am J Med 121:491-3. 2008
  3. ncbi request reprint Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study
    Robert A Wise
    Johns Hopkins School of Medicine, Baltimore, Maryland 21224, USA
    Arthritis Rheum 50:3994-4001. 2004
  4. ncbi request reprint The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study)
    Fredrick M Wigley
    Johns Hopkins University, Baltimore, Maryland 21224, USA
    Arthritis Rheum 52:2125-32. 2005
  5. ncbi request reprint Raynaud's phenomenon in mixed connective tissue disease
    Thomas Grader-Beck
    Division of Rheumatology, Johns Hopkins School of Medicine, 5200 Eastern Avenue, Suite 4100, Baltimore, MD 21224, USA
    Rheum Dis Clin North Am 31:465-81, vi. 2005
  6. ncbi request reprint Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases
    Reda E Girgis
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA
    J Heart Lung Transplant 24:1626-31. 2005
  7. pmc Paclitaxel modulates TGFbeta signaling in scleroderma skin grafts in immunodeficient mice
    Xialin Liu
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS Med 2:e354. 2005
  8. ncbi request reprint Evaluation of topoisomerase-1-specific CD8+ T-cell response in systemic sclerosis
    Francesco Boin
    Division of Rheumatology, The Johns Hopkins University School of Medicine, 5200 Eastern Ave, Mason F Lord Bldg, Center Tower, Ste 4100, Baltimore, MD 21224, USA
    Ann N Y Acad Sci 1062:137-45. 2005
  9. ncbi request reprint Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma
    Betty Chang
    Division of Pulmonary and Critical Care Medicine, University of New Mexico, Albuquerque, 87131, USA
    J Rheumatol 33:269-74. 2006
  10. ncbi request reprint Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension
    Lionel Schachna
    Johns Hopkins University, Baltimore, Maryland 21224, USA
    Arthritis Rheum 54:3954-61. 2006

Collaborators

Detail Information

Publications39

  1. ncbi request reprint Clinical practice. Raynaud's Phenomenon
    Fredrick M Wigley
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    N Engl J Med 347:1001-8. 2002
  2. ncbi request reprint "Still" ill?
    Peter K Wung
    Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Am J Med 121:491-3. 2008
  3. ncbi request reprint Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study
    Robert A Wise
    Johns Hopkins School of Medicine, Baltimore, Maryland 21224, USA
    Arthritis Rheum 50:3994-4001. 2004
    ..This study observed the effect of OPC-28326 on skin temperature and digital blood flow following an acute cold challenge in patients with Raynaud's phenomenon secondary to scleroderma...
  4. ncbi request reprint The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study)
    Fredrick M Wigley
    Johns Hopkins University, Baltimore, Maryland 21224, USA
    Arthritis Rheum 52:2125-32. 2005
    ..We sought to determine the point prevalence of undiagnosed PAH in community-based rheumatology practices...
  5. ncbi request reprint Raynaud's phenomenon in mixed connective tissue disease
    Thomas Grader-Beck
    Division of Rheumatology, Johns Hopkins School of Medicine, 5200 Eastern Avenue, Suite 4100, Baltimore, MD 21224, USA
    Rheum Dis Clin North Am 31:465-81, vi. 2005
    ..Therapeutic regimens include the traditional use of calcium channel blockers and novel vascular therapies...
  6. ncbi request reprint Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases
    Reda E Girgis
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA
    J Heart Lung Transplant 24:1626-31. 2005
    ..Scant data are available regarding PAH associated with the scleroderma spectrum of diseases (APAH-SSD). Here we review our experience with bosentan in these 2 groups...
  7. pmc Paclitaxel modulates TGFbeta signaling in scleroderma skin grafts in immunodeficient mice
    Xialin Liu
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS Med 2:e354. 2005
    ..Abnormal TGFbeta activation is implicated in the pathogenesis of SSc. Aberrant TGFbeta/Smad signaling can be controlled by stabilization of microtubules with paclitaxel...
  8. ncbi request reprint Evaluation of topoisomerase-1-specific CD8+ T-cell response in systemic sclerosis
    Francesco Boin
    Division of Rheumatology, The Johns Hopkins University School of Medicine, 5200 Eastern Ave, Mason F Lord Bldg, Center Tower, Ste 4100, Baltimore, MD 21224, USA
    Ann N Y Acad Sci 1062:137-45. 2005
    ..94%). This small-volume ex vivo assay may prove to be a sensitive and specific tool to assess disease activity and to monitor response to therapy in patients with scleroderma...
  9. ncbi request reprint Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma
    Betty Chang
    Division of Pulmonary and Critical Care Medicine, University of New Mexico, Albuquerque, 87131, USA
    J Rheumatol 33:269-74. 2006
    ..To determine risk factors for developing pulmonary hypertension (PH) in patients with scleroderma (SSc, systemic sclerosis)...
  10. ncbi request reprint Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension
    Lionel Schachna
    Johns Hopkins University, Baltimore, Maryland 21224, USA
    Arthritis Rheum 54:3954-61. 2006
    ..This study was undertaken to evaluate whether patients with systemic sclerosis (scleroderma), a systemic autoimmune rheumatic disorder, would receive similar benefit from this intervention...
  11. doi request reprint Systemic sclerosis (scleroderma) is unique among our rheumatic diseases. Preface
    Fredrick M Wigley
    Johns Hopkins Scleroderma Center, John Hopkins University, 5200 Eastern Avenue, Suite 4100, Mason F Lord Building, Center Tower, Baltimore, MD 21224, USA
    Rheum Dis Clin North Am 34:xi-xiii. 2008
  12. doi request reprint Often forgotten manifestations of systemic sclerosis
    Ami A Shah
    Division of Rheumatology, Johns Hopkins University, 5200 Eastern Avenue, Mason F Lord Building, Center Tower, Suite 4100, Baltimore, MD 21224, USA
    Rheum Dis Clin North Am 34:221-38; ix. 2008
    ....
  13. pmc Identification of candidate genes in scleroderma-related pulmonary arterial hypertension
    Dmitry N Grigoryev
    Division of Allergy and Clinical Immunology, Johns Hopkins University, Baltimore, MD 21224, USA
    Transl Res 151:197-207. 2008
    ..Deciphering the role of genes involved in vascular remodeling and PAH development may reveal new treatment targets for this devastating disorder...
  14. pmc T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease
    Francesco Boin
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Arthritis Rheum 58:1165-74. 2008
    ..The aim of this study was to investigate whether a polarized T cell phenotype in SSc is associated with lung disease or other clinical manifestations of SSc...
  15. ncbi request reprint Scleroderma patients with combined pulmonary hypertension and interstitial lung disease
    Betty Chang
    Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
    J Rheumatol 30:2398-405. 2003
    ..We studied the demographics, clinical features, and prognosis of individuals with both vascular and interstitial lung disease...
  16. ncbi request reprint Age and risk of pulmonary arterial hypertension in scleroderma
    Lionel Schachna
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Chest 124:2098-104. 2003
    ..To investigate whether age at disease onset is a risk factor for pulmonary arterial hypertension (PAH) in scleroderma...
  17. ncbi request reprint Targeting mediators of vascular injury in scleroderma
    Lionel Schachna
    Division of Rheumatology, Departments of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Curr Opin Rheumatol 14:686-93. 2002
    ..Finally, the authors look at the potential role of biomarkers as surrogate indicators of active vascular disease in scleroderma...
  18. ncbi request reprint Autoantibodies against B23, a nucleolar phosphoprotein, occur in scleroderma and are associated with pulmonary hypertension
    Danielle B Ulanet
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Arthritis Rheum 49:85-92. 2003
    ..To determine whether the abundant nucleolar phosphoprotein B23 is a target of autoantibodies in scleroderma, and to examine the clinical phenotype associated with these antibodies...
  19. ncbi request reprint Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon
    Peter A Merkel
    Harvard Medical School, Boston, Massachusetts, USA
    Arthritis Rheum 46:2410-20. 2002
    ....
  20. ncbi request reprint Recognition of Granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss
    Lionel Schachna
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Arthritis Rheum 46:1873-84. 2002
    ..To examine whether autoantibodies recognizing granzyme B (GB)-cleaved autoantigens are associated with ischemic digital loss (IDL) in limited systemic sclerosis (SSc)...
  21. ncbi request reprint Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma
    Laura K Hummers
    Division of Rheumatology, Johns Hopkins University, Baltimore, MD 21205, USA
    Rheum Dis Clin North Am 29:293-313. 2003
    ..Critical ischemia can cause deep tissue injury and digital loss. An aggressive approach to reversing an ischemic crisis is essential for preventing these severe events...
  22. ncbi request reprint Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients
    Irina G Luzina
    Research Service, Veterans Affairs Maryland Health Care System, Baltimore VA Medical Center, Room 3C 125, 10 North Greene Street, Baltimore, MD 21201, USA
    Arthritis Rheum 48:2262-74. 2003
    ..In the present study, we sought to determine whether activated CD8+ T cells contribute to pulmonary fibrosis in scleroderma patients through the production and activation of profibrotic mediators...
  23. ncbi request reprint Gene expression in bronchoalveolar lavage cells from scleroderma patients
    Irina G Luzina
    Research Service, Veterans Affairs Maryland Health Care System and Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Am J Respir Cell Mol Biol 26:549-57. 2002
    ....
  24. pmc Deficient Smad7 expression: a putative molecular defect in scleroderma
    Chunming Dong
    Division of Cardiology, Duke University Medical Center, 7504 Duke Hospital North, Box 3845, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 99:3908-13. 2002
    ..These results suggest that alterations in the Smad pathway, including marked Smad7 deficiency and Smad3 up-regulation, may be responsible for TGF-beta hyperresponsiveness observed in scleroderma...
  25. ncbi request reprint The impact of pain and symptoms of depression in scleroderma
    Lisa M Benrud-Larson
    Mayo Clinic, Rochester, MN, USA
    Pain 95:267-75. 2002
    ..Increased attention to effective management of pain and symptoms of depression in scleroderma will likely lead to improved functioning and quality of life...
  26. ncbi request reprint Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review
    Sheridan Henness
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Curr Opin Rheumatol 19:611-8. 2007
    ..Some data suggest some benefits to the use of the phosphodiesterase inhibitor sildenafil, the serotonin uptake inhibitor fluoxetine and the angiotensin receptor inhibitor losartan...
  27. ncbi request reprint Antiangiogenic plasma activity in patients with systemic sclerosis
    Mary Jo Mulligan-Kehoe
    Angiogenesis Research Center, Dartmouth Medical School, Lebanon, New Hampshire 03756, USA
    Arthritis Rheum 56:3448-58. 2007
    ..The aim of this study was to investigate the presence of antiangiogenic factors in patients with SSc...
  28. ncbi request reprint Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease
    Gordon K Lam
    J Rheumatol 34:1636-7. 2007
  29. ncbi request reprint Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease
    Shikha Mittoo
    Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Baltimore, MD 21224, USA
    Arthritis Rheum 56:4195-202. 2007
    ....
  30. ncbi request reprint Autoimmune disorders: nail signs and therapeutic approaches
    Noelle S Sherber
    Columbia University Medical Center, New York, New York 10032, USA
    Dermatol Ther 20:17-30. 2007
    ..Whereas oral calcium channel blockers remain the most convenient therapy, oral endothelin receptor antagonists and intravenous prostaglandins may be important therapeutic advances for ischemic digital vascular lesions...
  31. ncbi request reprint Bullous pemphigoid in a patient with systemic sclerosis (scleroderma)
    Noelle S Sherber
    J Rheumatol 33:2098. 2006
  32. ncbi request reprint Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis in scleroderma--a different kind of renal crisis
    Diane L Kamen
    Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    J Rheumatol 33:1886-8. 2006
    ..We suggest that the presence of ANCA be routinely evaluated when faced with renal failure in the setting of SSc...
  33. ncbi request reprint Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation
    Richard F Macko
    Department of Neurology, VA Maryland Health Care Center, Baltimore 21201, USA
    J Rheumatol 29:2565-70. 2002
    ..The relationship of these counteradhesive proteins to measures of platelet and endothelial cell activation was examined...
  34. ncbi request reprint Understanding, assessing and treating Raynaud's phenomenon
    Francesco Boin
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Curr Opin Rheumatol 17:752-60. 2005
    ..In this review, we outline how these new findings are leading to novel methods of assessment and new opportunities for specific targeted therapy...
  35. ncbi request reprint Treatment of scleroderma: an update
    Sangeeta D Sule
    Division of Rheumatology, Johns Hopkins University, Baltimore, MD 21205, USA
    Expert Opin Investig Drugs 12:471-82. 2003
    ..More experience in well-designed clinical trials is needed to define the role of these agents in treating scleroderma...
  36. ncbi request reprint Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis
    Megan E B Clowse
    Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Rheumatol 30:1341-3. 2003
    ..This case illustrates the risk of severe digital ischemia and digital loss in patients with scleroderma during chemotherapy with carboplatin and gemcitabine...
  37. ncbi request reprint Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, Los Angeles, California, USA
    J Rheumatol 32:832-40. 2005
    ....
  38. ncbi request reprint Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study
    Dinesh Khanna
    David Geffen School of Medicine, University of California, Los Angeles, USA
    Arthritis Rheum 52:592-600. 2005
    ....
  39. ncbi request reprint Disease severity as a predictor of outcome in scleroderma
    Allan C Gelber
    Division of Molecular and Clinical Rheumatology, Johns Hopkins University, Baltimore, MD 21205, USA
    Lancet 359:277-9. 2002